$BDSI ascending triangle $2.00 Sitting on 13 day
Post# of 40
(Total Views: 568)
Posted On: 03/11/2017 1:08:11 PM
$BDSI ascending triangle $2.00
Sitting on 13 day simple moving average.
Nasdaq CM.
10/Q & 10/K Results on Friday, March 17
website
Last ten trades
33% x 75% Strong buy
Low float
Shares Outstanding 54.12M
Float 43.23M
% Held by Insiders 8.32%
% Held by Institutions 80.10%
Shares Short 3 4.33M
Short Ratio 10.97
Short % of Float 8.67%
Shares Short (prior month) 4.35M
Stock technical Analysis
News
and filings
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. It offers ONSOLIS , a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer marketed under the BREAKYL name in the US, Canda, and Europe, as well as PAINKYL name in Taiwan; BUNAVAIL , a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA , a buprenorphine buccal film for the treatment of chronic pain. The company also develops Clonidine Topical Gel , which is in Phase III clinical trial to treat painful diabetic neuropathy and other indications; and Buprenorphine Depot Injection, an injectable, extended release, microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Arcion Therapeutics, Inc.; Evonik Corporation; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
BUNAVAIL: Fight The Fog Of Addiction
About Opioid Dependence:
Opioid dependence is a significantly undertreated condition in the U.S., with approximately 2.5 million people dependent on prescription opioids according to the National Survey on Drug Use and Health, conducted by the U.S. Department of Health and Human Services.
Sitting on 13 day simple moving average.
Nasdaq CM.
10/Q & 10/K Results on Friday, March 17
website
Last ten trades
33% x 75% Strong buy
Low float
Shares Outstanding 54.12M
Float 43.23M
% Held by Insiders 8.32%
% Held by Institutions 80.10%
Shares Short 3 4.33M
Short Ratio 10.97
Short % of Float 8.67%
Shares Short (prior month) 4.35M
Stock technical Analysis
News
and filings
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. It offers ONSOLIS , a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer marketed under the BREAKYL name in the US, Canda, and Europe, as well as PAINKYL name in Taiwan; BUNAVAIL , a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA , a buprenorphine buccal film for the treatment of chronic pain. The company also develops Clonidine Topical Gel , which is in Phase III clinical trial to treat painful diabetic neuropathy and other indications; and Buprenorphine Depot Injection, an injectable, extended release, microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. It has a licensing and development agreement with Endo Pharmaceuticals, Inc.; Arcion Therapeutics, Inc.; Evonik Corporation; and Meda AB. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
BUNAVAIL: Fight The Fog Of Addiction
About Opioid Dependence:
Opioid dependence is a significantly undertreated condition in the U.S., with approximately 2.5 million people dependent on prescription opioids according to the National Survey on Drug Use and Health, conducted by the U.S. Department of Health and Human Services.
(0)
(0)